CVRx Q2 revenue $9.5M (+89% YoY); raises FY 2023 revenue guidance

CVRx, Inc.

2023-Q2 EPS reported -$1.11 revenue$17,479,000

Q2 total revenue $9.5M, +89% YoY; US HF revenue $8.3M, +119% YoY.
Net loss $11.7M ($0.56 per share) vs $11.1M ($0.54 per share) in Q2 2022.
Active US implanting centers grew to 140, up 97% from June 2022.
FY 2023 revenue guidance raised to $37.0-38.5M (from $35.5-38.0M).
PMA supplement filed with FDA for Barostim indication expansion in June 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVRx, Inc. reported the quarter ended June 30, 2023 results: revenue $9.5 million, net income $11.7 million, EPS $0.56 per share. Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $9.5 million
Net income: $11.7 million
EPS: $0.56 per share
Guidance: raised
Result: reported results

Exact text from the filing

diseases, today announced its financial and operating results for the second quarter of 2023. Recent Highlights · Total revenue for the second quarter of 2023 was $ 9.5 million, an increase of 89 % over prior year quarter · U.S. Heart Failure (HF) revenue for the second quarter of 2023 was $ 8.3 million compared to $ 3.8 in the prior year quarter, an

View on SEC.gov

53 earnings releases filed in the last 30 days. Browse all earnings releases →

CVRx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-083850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.